Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 25, 2019 01:05 ET | Source: Sequana Medical NV

Sequana Medical announces 2019 Half Year Results and Year-to-date Business Update

Regulated information Continued strong progress since IPO in February 2019: Commenced POSEIDON pivotal study to support approval of the alfapump® in the U.S. & CanadaAchieved clinical...
September 25, 2019 01:00 ET | Source: Sequana Medical NV

Sequana Medical announces first patient enrolled in North American alfapump® pivotal study (POSEIDON)

Study aims to support the approval of the alfapump in U.S. and CanadaResults anticipated by mid-2021U.S. launch of the alfapump planned for H1 2022 Ghent, BELGIUM – 25 September 2019 – Sequana...
September 19, 2019 01:00 ET | Source: Sequana Medical NV

Sequana Medical appoints leading experts as Heart Failure Scientific Advisors

Dr. Butler, Dr. Costanzo, Dr. Tang and Dr. Testani to advise on alfapump® DSR development Ghent, BELGIUM – 19 September 2019 – Sequana Medical NV (Euronext...
August 14, 2019 01:00 ET | Source: Sequana Medical NV

Sequana Medical announces date change for Half Year 2019 Business Update and Financial Results

Results and conference call with live webcast will take place on 25 September 2019 Ghent, BELGIUM – 14 August 2019 – Sequana Medical NV (Euronext Brussels: SEQUA), innovators in the management...
June 04, 2019 01:00 ET | Source: Sequana Medical NV

Sequana Medical announces unconditional IDE approval from U.S. FDA to start alfapump® pivotal study (POSEIDON)

REGULATED INFORMATION – INSIDE INFORMATION alfapump pivotal study for treatment of recurrent or refractory ascites due to liver cirrhosis Optimised clinical trial design of up to 50 patients...
May 27, 2019 02:30 ET | Source: Sequana Medical NV

Sequana Medical announces presentation of positive DSR clinical proof-of-concept data demonstrating potential in volume overload due to heart failure

REGULATED INFORMATION – INSIDE INFORMATION First-in-human single dose DSR study meets primary and secondary endpoints Direct Sodium Removal (DSR) was safe & well-tolerated Substantially higher...
May 23, 2019 12:00 ET | Source: Sequana Medical NV

Sequana Medical announces results of Annual General Meeting of Shareholders

Experienced MedTech Executive Jason Hannon appointed as Non-Executive Director Ghent, BELGIUM – 23 May 2019 (18:00 CEST) – Sequana Medical NV (Euronext Brussels: SEQUA), a commercial stage medical...
May 21, 2019 01:00 ET | Source: Sequana Medical NV

Sequana Medical zal een webcast houden op 27 mei 2019

Vennootschap zal late-breaking abstract bespreken van DSR-therapie voor volumeoverbelasting bij hartfalen die wordt voorgesteld op het Heart Failure 2019 congres Gent, BELGIË – 21 mei 2019 –...
May 21, 2019 01:00 ET | Source: Sequana Medical NV

Sequana Medical to host webcast on 27 May 2019

Company to discuss late-breaking abstract of DSR therapy for volume overload in heart failure presented at the Heart Failure 2019 Congress Ghent, BELGIUM – 21 May 2019 – Sequana Medical NV...
May 15, 2019 01:00 ET | Source: Sequana Medical NV

Sequana Medical kondigt aan dat de alfapump® werd opgenomen in de Duitse behandelingsrichtlijnen (DGVS) voor complicaties van levercirrose

Bijkomende validatie bouwt verder op de FDA1 Breakthrough Device status in de VS en de opname in de aanbevelingen van NICE2 in het VK en in de EASL3 richtlijnen Gent, BELGIË – 15 mei 2019 – Sequana...